192 related articles for article (PubMed ID: 30463528)
1. Effects of PKM2 on global metabolic changes and prognosis in hepatocellular carcinoma: from gene expression to drug discovery.
Lv WW; Liu D; Liu XC; Feng TN; Li L; Qian BY; Li WX
BMC Cancer; 2018 Nov; 18(1):1150. PubMed ID: 30463528
[TBL] [Abstract][Full Text] [Related]
2. PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma.
Liu WR; Tian MX; Yang LX; Lin YL; Jin L; Ding ZB; Shen YH; Peng YF; Gao DM; Zhou J; Qiu SJ; Dai Z; He R; Fan J; Shi YH
Oncotarget; 2015 Jan; 6(2):846-61. PubMed ID: 25514599
[TBL] [Abstract][Full Text] [Related]
3. Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma.
Hu W; Lu SX; Li M; Zhang C; Liu LL; Fu J; Jin JT; Luo RZ; Zhang CZ; Yun JP
Oncotarget; 2015 Mar; 6(9):6570-83. PubMed ID: 25788265
[TBL] [Abstract][Full Text] [Related]
4. Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma.
Dayton TL; Gocheva V; Miller KM; Israelsen WJ; Bhutkar A; Clish CB; Davidson SM; Luengo A; Bronson RT; Jacks T; Vander Heiden MG
Genes Dev; 2016 May; 30(9):1020-33. PubMed ID: 27125672
[TBL] [Abstract][Full Text] [Related]
5. Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma.
Chen Z; Lu X; Wang Z; Jin G; Wang Q; Chen D; Chen T; Li J; Fan J; Cong W; Gao Q; He X
Oncotarget; 2015 Feb; 6(4):2538-48. PubMed ID: 25576919
[TBL] [Abstract][Full Text] [Related]
6. HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma.
Xu Q; Tu J; Dou C; Zhang J; Yang L; Liu X; Lei K; Liu Z; Wang Y; Li L; Bao H; Wang J; Tu K
Mol Cancer; 2017 Dec; 16(1):178. PubMed ID: 29262861
[TBL] [Abstract][Full Text] [Related]
7. Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis.
Wong CC; Au SL; Tse AP; Xu IM; Lai RK; Chiu DK; Wei LL; Fan DN; Tsang FH; Lo RC; Wong CM; Ng IO
PLoS One; 2014; 9(12):e115036. PubMed ID: 25541689
[TBL] [Abstract][Full Text] [Related]
8. miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma.
Liu AM; Xu Z; Shek FH; Wong KF; Lee NP; Poon RT; Chen J; Luk JM
PLoS One; 2014; 9(1):e86872. PubMed ID: 24466275
[TBL] [Abstract][Full Text] [Related]
9. COX-2 induces apoptosis-resistance in hepatocellular carcinoma cells via the HIF-1α/PKM2 pathway.
Wang Q; Lu D; Fan L; Li Y; Liu Y; Yu H; Wang H; Liu J; Sun G
Int J Mol Med; 2019 Jan; 43(1):475-488. PubMed ID: 30365092
[TBL] [Abstract][Full Text] [Related]
10. Ectosomal PKM2 Promotes HCC by Inducing Macrophage Differentiation and Remodeling the Tumor Microenvironment.
Hou PP; Luo LJ; Chen HZ; Chen QT; Bian XL; Wu SF; Zhou JX; Zhao WX; Liu JM; Wang XM; Zhang ZY; Yao LM; Chen Q; Zhou D; Wu Q
Mol Cell; 2020 Jun; 78(6):1192-1206.e10. PubMed ID: 32470318
[TBL] [Abstract][Full Text] [Related]
11. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
Martin SP; Fako V; Dang H; Dominguez DA; Khatib S; Ma L; Wang H; Zheng W; Wang XW
J Exp Clin Cancer Res; 2020 Jun; 39(1):99. PubMed ID: 32487192
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of pyruvate kinase M2 isoform inhibits cell motility in hepatocellular carcinoma cells.
Chen YL; Song JJ; Chen XC; Xu W; Zhi Q; Liu YP; Xu HZ; Pan JS; Ren JL; Guleng B
World J Gastroenterol; 2015 Aug; 21(30):9093-102. PubMed ID: 26290635
[TBL] [Abstract][Full Text] [Related]
13. Pyruvate kinase M2 interacts with nuclear sterol regulatory element-binding protein 1a and thereby activates lipogenesis and cell proliferation in hepatocellular carcinoma.
Zhao X; Zhao L; Yang H; Li J; Min X; Yang F; Liu J; Huang G
J Biol Chem; 2018 Apr; 293(17):6623-6634. PubMed ID: 29514980
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of Pyruvate Kinase M2 in Tumor Tissues Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
Zhao R; Li L; Yang J; Niu Q; Wang H; Qin X; Zhu N; Shi A
Pathol Oncol Res; 2020 Apr; 26(2):853-860. PubMed ID: 30852741
[TBL] [Abstract][Full Text] [Related]
15. Metabolic signature genes associated with susceptibility to pyruvate kinase, muscle type 2 gene ablation in cancer cells.
Jung Y; Jang YJ; Kang MH; Park YS; Oh SJ; Lee DC; Xie Z; Yoo HS; Park KC; Yeom YI
Mol Cells; 2013 Apr; 35(4):335-41. PubMed ID: 23515579
[TBL] [Abstract][Full Text] [Related]
16. PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma.
Feng J; Wu L; Ji J; Chen K; Yu Q; Zhang J; Chen J; Mao Y; Wang F; Dai W; Xu L; Wu J; Guo C
J Exp Clin Cancer Res; 2019 May; 38(1):204. PubMed ID: 31101057
[TBL] [Abstract][Full Text] [Related]
17. PKM2 regulates hepatocellular carcinoma cell epithelial-mesenchymal transition and migration upon EGFR activation.
Fan FT; Shen CS; Tao L; Tian C; Liu ZG; Zhu ZJ; Liu YP; Pei CS; Wu HY; Zhang L; Wang AY; Zheng SZ; Huang SL; Lu Y
Asian Pac J Cancer Prev; 2014; 15(5):1961-70. PubMed ID: 24716919
[TBL] [Abstract][Full Text] [Related]
18. E3 ligase ZFP91 inhibits Hepatocellular Carcinoma Metabolism Reprogramming by regulating PKM splicing.
Chen D; Wang Y; Lu R; Jiang X; Chen X; Meng N; Chen M; Xie S; Yan GR
Theranostics; 2020; 10(19):8558-8572. PubMed ID: 32754263
[No Abstract] [Full Text] [Related]
19. HDAC8-dependent deacetylation of PKM2 directs nuclear localization and glycolysis to promote proliferation in hepatocellular carcinoma.
Zhang R; Shen M; Wu C; Chen Y; Lu J; Li J; Zhao L; Meng H; Zhou X; Huang G; Zhao X; Liu J
Cell Death Dis; 2020 Dec; 11(12):1036. PubMed ID: 33279948
[TBL] [Abstract][Full Text] [Related]
20. Dauricine upregulates the chemosensitivity of hepatocellular carcinoma cells: Role of repressing glycolysis via miR-199a:HK2/PKM2 modulation.
Li W; Qiu Y; Hao J; Zhao C; Deng X; Shu G
Food Chem Toxicol; 2018 Nov; 121():156-165. PubMed ID: 30171973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
